tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Prescient Therapeutics Expands PTX-100 Clinical Trials to U.S.

Story Highlights
Prescient Therapeutics Expands PTX-100 Clinical Trials to U.S.

Elevate Your Investing Strategy:

Prescient Therapeutics Limited ( (AU:PTX) ) just unveiled an update.

Prescient Therapeutics Limited has announced the initiation of its first U.S. site for the Phase 2a clinical trial of PTX-100 at the VCU Massey Comprehensive Cancer Center, marking a significant milestone in the treatment of refractory/relapsed Cutaneous T-Cell Lymphoma (CTCL). This expansion into the U.S. complements the ongoing trials in Australia and represents a crucial step in broadening patient access to this innovative therapy, potentially strengthening Prescient’s position in the oncology market.

More about Prescient Therapeutics Limited

Prescient Therapeutics Limited is a clinical stage oncology company focused on developing personalized medicine approaches to cancer, including targeted and cellular therapies. Their primary products include PTX-100, a first-in-class compound targeting cancer growth enzymes, and CellPryme technologies that enhance cell therapy performance.

Average Trading Volume: 997,562

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$33.82M

For a thorough assessment of PTX stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1